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Previewsto fight to use the knowledge that we have
in hand, such as the elegant work by Kool
et al. (2014).
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A PI3Kd-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent
B cell non-Hodgkin’s lymphomas. In these malignancies, the PI3K pathway is not mutationally activated
as inmany other cancers, but it is important formediating supportive cues from the cancermicroenvironment
and the B cell antigen receptor.Major cancer drug development efforts
currently focus on targeting PI3K
pathway components based on the over-
whelming genetic evidence in support of
a role for this pathway in malignancy
(Fruman and Rommel, 2014). The PI3K
pathway has multiple nodes and is medi-
ated by eight distinct PI3K catalytic
subunits, among which the p110 sub-
units (p110a, b, g, and d) transduce
signals downstream of tyrosine kinases,
G protein-coupled receptors, Ras, and
other small GTPases. Whereas p110a
and p110b show broad tissue dis-
tribution, p110g and p110d are highly
expressed in leukocytes and control
immune responses. PIK3CA, which
encodes p110a, is frequently mutated
and activated in solid tumors, but not
in hematological malignancies. Constitu-
tively activating p110d mutations have
recently been found in a human primary
immunodeficiency disorder without
apparently predisposing to cancer (Fru-man and Rommel, 2014). Other PI3K cat-
alytic subunits have not been found to be
mutated in disease.
Two recent studies report impressive
clinical activity of idelalisib, an oral ATP-
competitive and reversible p110d inhi-
bitor, in relapsed chronic lymphocytic
leukemia (CLL) and indolent non-Hodg-
kin’s lymphomas (iNHLs). All patients
were heavily pretreated and/or not suffi-
ciently fit to undergo standard cytotoxic
chemotherapy. Idelalisib was tested in
combination with rituximab in CLL (Fur-
man et al., 2014) and as a single agent in
iNHL (Gopal et al., 2014). Rituximab is
currently commonly used, although not
approved, as a single agent for treating
relapsed CLL.
NHLs are a heterogeneous group of
lymphomas that arise primarily in the
lymph nodes, and CLL is usually an indo-
lent tumor with accumulation of malig-
nant B cells in lymphatic tissues, bone
marrow, and blood. The course of thesediseases is highly variable, with some
patients never needing treatment. For
those who do, the standard approach is
chemotherapy, which can lead to signifi-
cant toxicities and immunosuppression,
and most patients will relapse. Recent
years have witnessed the development
of more targeted therapies for hemato-
logical malignancies, in particular, small
molecule inhibitors of kinases that
mediate intracellular signal transduction
in lymphocytes, such as Syk and Btk.
Such agents would be expected to be
more tumor selective and better toler-
ated. The rationale for targeting p110d
in B cell malignancy is its key role
in signal transduction downstream of
various B cell receptors, including the
B cell antigen receptor (BCR), cytokine/
chemokine receptors, and adhesion
molecules (Figure 1), contributing to the
regulation of proliferation, differentiation,
migration, and survival (Fruman and
Rommel, 2011).5, March 17, 2014 ª2014 Elsevier Inc. 269
Figure 1. Role of PI3Kd in CLL Cell ‘‘Life Cycle’’
CLL cells circulate in the peripheral blood and are attracted by chemokine
gradients to lymph nodes and bone marrow, where they encounter signals
from adhesion molecules (such as integrins and selectins), cytokines and
chemokines, costimulatory molecules (such as CD40), and possibly also
BCR signaling. PI3Kd, Btk, and Syk are important intracellular transducers of
these stimuli, and interference with their activity results in both release of the
CLL cells into the circulation (lymphocytosis) and blockade of their re-entry.
Such cycles have not been demonstrated for NHL, but these cells are also
expected to require these signaling molecules for trophic signals from their
microenvironment.
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PreviewsThe CLL study was a ran-
domized, double-blind phase
III trial with 220 patients, who
were all given rituximab
in combination with either
idelalisib or placebo (Furman
et al., 2014). The study was
stopped early by the safety
monitoring board based on
overwhelming efficacy, with
the idelalisib group showing
a significantly higher overall
response rate (81% versus
13%) and overall survival
(92% versus 80% at 12
months). Median duration
of progression-free survival
was 5.5 months in the non-
idelalisib cohort and was
not reached in the idelalisib
group. The iNHL study was
a single arm, phase II trial in
which 125 patients were
given idelalisib continuously
until disease progression or
toxicity (Gopal et al., 2014).
There was a 57% overall
response rate that was
similar across all iNHL sub-
types. Median progression-
free survival was 11 months,
and median overall survival
was 20.3 months, with over-
all survival at 1 year esti-
mated to be 80%. Overall,
idelalisib was well tole-
rated, with rapid, durable
responses independent of
previous therapies or the
genetic landscape of the
tumors. Of the patients
treated with idelalisib,R90%
showed a reduction in lymph
node size.What is thebasis for this impressive clin-
ical impact of p110d blockade? An impor-
tant clue comes from the observation that
idelalisib rapidly induces lymphocytosis,
an increase in the number of circulating
lymphocytes, in CLL patients, correlating
with lymph node shrinkage, a phe-
nomenon also observed with inhibitors of
Syk and Btk (Burger and Montserrat,
2013). In B cells, Btk, Syk, and p110d are
part of a signaling network involved in the
interaction and communication of B cells
with their environment, which is of critical
importance in the life cycle of CLL cells
(Figure 1). This cycle involves migration270 Cancer Cell 25, March 17, 2014 ª2014 Eof leukemic cells from the peripheral blood
to the lymph nodes, spleen, and bone
marrow, where they become activated by
microenvironmental stimuli, includingcos-
timulatory molecules, chemo/cytokines,
cell adhesion, and possibly also antigen-
stimulation of the BCR, leading to their
survival and proliferation. CLL cells then
egress back into the circulation, where
they are mostly noncycling and are
thought to die unless they home back to
the tissue compartment (Burger and
Montserrat, 2013).
Inhibition of p110d, like that of Btk and
Syk, may interfere with the CLL cycle atlsevier Inc.various levels, leading to
mobilization of tissue-resi-
dent CLL cells into the blood
and blocking re-entry to the
stroma. Sustained interfer-
ence with this recirculation
cycle may make CLL cells
‘‘run out of fuel,’’ and the
lack of trophic signals sensi-
tize them to combination
treatments. It is likely that
the dynamic life cycle of CLL
could explain why this dis-
ease, among the different B
cell malignancies, is the
most responsive to B cell
signaling blockers. Indeed,
the in vivo mechanism of
action of p110d inhibition in
NHL is less clear, although
intracellular signaling in these
B cell malignancies is also
known to be partially con-
trolled by PI3Kd. While inter-
ference with BCR signaling
is often posited as the key
mechanism of therapeutic
activity of inhibitors targeting
p110d, Btk, or Syk, its
relative importance com-
pared to other B cell stimuli
is unclear. It is also not clear
if p110d inhibitors have direct
antiproliferative or cytotoxic
effects in vivo, given that
they only have a modest
impact on in vitro cell prolifer-
ation and survival of primary
B cell malignancies.
Residual PI3K activity pre-
sent in immune cells upon
p110d inhibition by idelalisib
might explain its lack of overt
immune suppression. Inhibi-tors that block multiple p110 isoforms
are in clinical trials for treating solid
tumors (Fruman and Rommel, 2014). As
these compounds more effectively block
leukocyte signaling than p110d-selective
inhibitors (Iyengar et al., 2013), should
they also be tested in hematological
malignancies? While broad(er) spectrum
PI3K inhibitors would indeed hit the
malignant cells harder, they might be
less well tolerated and be more immune
suppressive upon long-term administra-
tion. Normal B cell development is only
modestly affected upon p110d inactiva-
tion, but is blocked upon co-inactivation
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Previewsof p110a (Ramadani et al., 2010). Com-
bined inactivation of the leukocyte selec-
tive p110d and p110g during mouse
development results in severe immune
defects (Ji et al., 2007), but temporary
co-targeting of these kinases might be
of therapeutic benefit, as shown in a
mouse model of T cell leukemia (Subra-
maniam et al., 2012).
Many new targeted therapies for B cell
malignancy are being developed, offering
a bewildering number of possible drug
combinations and dose regimens. One
consideration will be drug tolerability,
and the available evidence suggests that
p110d inhibitors score well in this respect.
It will be important to assess how long
p110d has to be inhibited in order to
obtain durable effects. Not all patients
respond to p110d or other targeted thera-
pies, and it will be critical to identify bio-
markers that predict and/or monitor drug
responsiveness (Woyach et al., 2014).
The research and development that
underpins the progress represented by
idelalisib is a prime example of the identi-fication and exploitation of a key vulnera-
bility in cancer cells. The hope is to un-
cover more such druggable critical
nodes in the future and to do it quicker.ACKNOWLEDGMENTS
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